Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent & Trademark Office (the USPTO) has granted US-based biotechnology firm Neptune Technologies & Bioressources a new continuation patent (US Patent No. 8,680,080) relating to the treatment of Alzheimer's disease (AD).
Subscribe to our email newsletter
The patent, which is the company’s first specifically targeting neurological conditions, is granted for the US market and is valid until 2022.
The company said that the claims focus on treating AD by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises DHA and EPA.
Neptune president and CEO Henri Harland said the announcement provides additional strength to our patent estate and highlights the company’s commitment to continue to protect and build this valuable asset for both its nutraceutical and pharmaceutical businesses.
"Neurological disorders, such as Alzheimer’s, are growing and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out," Harland said.
"In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurological pharmaceutical applications."
Neptune is focused in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (‘PUFAs’).
The company has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to its distributors who commercialize them under their private label primarily in the US, European and Australian nutraceutical markets.